Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the recipient of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 65,500 shares, a decline of 24.9% from the January 15th total of 87,200 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average daily trading volume, of 28,700 shares, the short-interest ratio is currently 2.3 days.

Insider Buying and Selling at Anebulo Pharmaceuticals

In related news, Director Aron R. English purchased 10,101,010 shares of Anebulo Pharmaceuticals stock in a transaction on Monday, December 23rd. The shares were purchased at an average price of $0.99 per share, for a total transaction of $9,999,999.90. Following the transaction, the director now owns 15,467,300 shares of the company’s stock, valued at approximately $15,312,627. This represents a 188.23 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 85.90% of the company’s stock.

Institutional Trading of Anebulo Pharmaceuticals

A hedge fund recently raised its stake in Anebulo Pharmaceuticals stock. Nantahala Capital Management LLC raised its stake in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) by 494.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,036,325 shares of the company’s stock after purchasing an additional 2,525,252 shares during the quarter. Nantahala Capital Management LLC owned 11.71% of Anebulo Pharmaceuticals worth $5,101,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 28.40% of the company’s stock.

Anebulo Pharmaceuticals Stock Performance

ANEB stock remained flat at $1.33 during trading on Friday. The company had a trading volume of 1,654 shares, compared to its average volume of 12,972. The business’s fifty day simple moving average is $1.51 and its 200 day simple moving average is $1.73. Anebulo Pharmaceuticals has a fifty-two week low of $0.80 and a fifty-two week high of $3.30.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last posted its quarterly earnings results on Friday, February 14th. The company reported ($0.09) earnings per share for the quarter. Equities analysts predict that Anebulo Pharmaceuticals will post -0.52 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Benchmark reissued a “speculative buy” rating and issued a $8.00 price objective on shares of Anebulo Pharmaceuticals in a research note on Tuesday, November 19th.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.